PE121799A1 - Uso de progestina para el control del sangrado - Google Patents

Uso de progestina para el control del sangrado

Info

Publication number
PE121799A1
PE121799A1 PE1998000990A PE00099098A PE121799A1 PE 121799 A1 PE121799 A1 PE 121799A1 PE 1998000990 A PE1998000990 A PE 1998000990A PE 00099098 A PE00099098 A PE 00099098A PE 121799 A1 PE121799 A1 PE 121799A1
Authority
PE
Peru
Prior art keywords
progestin
endometry
refers
causing
control bleeding
Prior art date
Application number
PE1998000990A
Other languages
English (en)
Inventor
Ziegler Dominique De
William J Bologna
Howard L Levine
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of PE121799A1 publication Critical patent/PE121799A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

SE REFIERE AL USO VAGINAL CICLICO DE PROGESTINA EN UN POLIMERO DE ACIDO POLICARBOXILICO RETICULADO, INSOLUBLE EN AGUA Y QUE SE HINCHA CON EL AGUA, DE PREFERENCIA SE UTILIZA DE 45 mg A 90 mg DE PROGESTERONA DURANTE PARTE DE CADA CICLO, O DOS VECES POR SEMANA; TAMBIEN SE REFIERE AL USO EN CONJUNTO CON ESTROGENO. EL USO DE PROGESTINA PUEDE SER UTIL PARA PROVOCAR Y MANTENER UNA AMENORREA DURANTE LA ADMINISTRACION CONSTANTE DE PROGESTINA, CAUSAR UNA TRANSFORMACION SECRETORA DEL ENDOMETRIO, TRATAR LA AMENORREA Y CAUSAR UNA ATROFIA DEL ENDOMETRIO
PE1998000990A 1997-10-21 1998-10-21 Uso de progestina para el control del sangrado PE121799A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6348597P 1997-10-21 1997-10-21
US09/170,326 US6306914B1 (en) 1997-10-21 1998-10-13 Progestin therapy for maintaining amenorrhea

Publications (1)

Publication Number Publication Date
PE121799A1 true PE121799A1 (es) 1999-12-17

Family

ID=26743461

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1998000990A PE121799A1 (es) 1997-10-21 1998-10-21 Uso de progestina para el control del sangrado

Country Status (19)

Country Link
US (3) US6306914B1 (es)
EP (1) EP1032399A1 (es)
JP (1) JP2003535015A (es)
KR (1) KR100581308B1 (es)
CN (1) CN1147301C (es)
AR (1) AR013981A1 (es)
AU (1) AU742166C (es)
BR (1) BR9813262A (es)
CA (2) CA2649671A1 (es)
HU (1) HUP0004133A3 (es)
IL (1) IL135742A (es)
MX (1) MXPA00003972A (es)
MY (1) MY121743A (es)
NO (1) NO326856B1 (es)
NZ (1) NZ504066A (es)
PE (1) PE121799A1 (es)
RO (1) RO121319B1 (es)
RU (2) RU2261099C2 (es)
WO (1) WO1999020282A1 (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
US20040191276A1 (en) * 1999-11-30 2004-09-30 Cutispharma, Inc. Compositions and kits for compounding pharmaceuticals
US8425892B2 (en) * 2001-10-29 2013-04-23 Columbia Laboratories, Inc. Extended, controlled-release pharmaceutical compositions using charged polymers
HU230759B1 (hu) * 2001-12-05 2018-03-28 Teva Women's Health, Inc. Teherbeesés megakadályozására és menstruációs tünetek enyhítésére vagy kiküszöbölésére alkalmas orális készítmények
AU2003239869A1 (en) * 2002-05-23 2003-12-12 Michael Holick Use of a parathyroid hormone peptide analogs for the treatment of vaginal atrophy
AU2003297534A1 (en) * 2002-12-24 2004-07-22 Ovion, Inc. Contraceptive device and delivery system
EP1624848A4 (en) * 2003-05-02 2009-02-25 Duramed Pharmaceuticals Inc METHOD FOR HORMONY TREATMENT WITH CONTRAZEPTVA SCHEMATES WITH EXTENDED CYCLE
ATE419855T1 (de) * 2003-06-25 2009-01-15 Bayer Schering Pharma Ag Therapie für hormonersatz und depression enthaltend dienogest
NZ585546A (en) * 2003-07-16 2011-10-28 Teva Womens Health Inc Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
EP1761231A1 (en) * 2004-06-07 2007-03-14 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub
US20070111975A1 (en) 2004-10-07 2007-05-17 Duramed Pharmaceuticals, Inc. Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
EP2289486A1 (en) * 2005-12-27 2011-03-02 Teva Women's Health, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
US20070264309A1 (en) * 2006-01-20 2007-11-15 Chollet Janet A Method Of Treating Atrophic Vaginitis
US8235047B2 (en) 2006-03-30 2012-08-07 Conceptus, Inc. Methods and devices for deployment into a lumen
BRPI0711525A2 (pt) * 2006-06-02 2011-11-01 Pear Tree Women S Health Care composição farmacêutica e método para tratar sintomas de vaginite atrófica
GB0616444D0 (en) * 2006-08-18 2006-09-27 Reckitt Benckiser Nv Detergent composition
US20100028447A1 (en) 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
DK2359807T3 (en) 2008-02-04 2017-10-16 Ferring Bv Monolithic vaginal rings comprising progesterone and methods of preparation and use thereof
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドＴｈｅｒａｐｅｕｔｉｃｓｍｄ， Ｉｎｃ． 天然の併用ホルモン補充療法剤及び療法
MX2016013693A (es) 2014-07-29 2017-10-31 Therapeuticsmd Inc Crema transdermica.
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
RU2697369C1 (ru) * 2018-12-21 2019-08-13 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Способ дифференциальной диагностики функциональной гипоталамической аменореи на фоне стресса и энергетического дефицита
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113288865B (zh) * 2021-06-28 2022-03-08 浙江仙琚制药股份有限公司 一种黄体酮阴道凝胶剂的制备方法
CN114983929A (zh) * 2022-05-16 2022-09-02 安徽万邦医药科技股份有限公司 一种稳定的黄体酮缓释凝胶及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151286T1 (de) 1983-11-14 1997-04-15 Columbia Lab Inc Bioadhäsive mittel
USD345211S (en) 1992-04-06 1994-03-15 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
USD375352S (en) 1994-03-14 1996-11-05 Columbia Laboratories, Inc. Dispensing vial for feminine hygiene products

Also Published As

Publication number Publication date
NO20002084L (no) 2000-06-21
HUP0004133A3 (en) 2001-09-28
NO20002084D0 (no) 2000-04-19
HUP0004133A2 (hu) 2001-05-28
KR100581308B1 (ko) 2006-05-22
MY121743A (en) 2006-02-28
BR9813262A (pt) 2000-08-22
US6593317B1 (en) 2003-07-15
CA2307615A1 (en) 1999-04-29
RU2005101612A (ru) 2006-07-10
WO1999020282A1 (en) 1999-04-29
CA2649671A1 (en) 1999-04-29
CN1147301C (zh) 2004-04-28
AU1191499A (en) 1999-05-10
AR013981A1 (es) 2001-01-31
RU2261099C2 (ru) 2005-09-27
NZ504066A (en) 2002-11-26
AU742166C (en) 2005-07-14
KR20010031299A (ko) 2001-04-16
MXPA00003972A (es) 2004-04-21
JP2003535015A (ja) 2003-11-25
CN1282250A (zh) 2001-01-31
RU2330667C2 (ru) 2008-08-10
IL135742A (en) 2004-09-27
EP1032399A1 (en) 2000-09-06
US6306914B1 (en) 2001-10-23
NO326856B1 (no) 2009-03-02
AU742166B2 (en) 2001-12-20
US20010031747A1 (en) 2001-10-18
IL135742A0 (en) 2001-05-20
RO121319B1 (ro) 2007-03-30

Similar Documents

Publication Publication Date Title
PE121799A1 (es) Uso de progestina para el control del sangrado
BR9709934A (pt) Kit de terapia de reposição hormonal e/ou contraceptivo uso de unidades de dosagem diária consistindo essecialmente de um progestogênio e processo de preparação de um sistema de liberação de droga
DE69620241D1 (de) Gonadotropin releasing hormon- antagonisten
AR028809A1 (es) Un metodo anticonceptivo y una unidad anticonceptiva oral trifasica
DE19680582D2 (de) Hormonpflaster
ES2132645T3 (es) Uso en una composicion farmaceutica.
RU2000112650A (ru) Прогестинотерапия с регулируемым кровотечением
CA2292402A1 (en) Intra-vaginal device for pigs
ATE173603T1 (de) Behandlung von erektionversagen
BR9612207A (pt) Processo e kit para contracepções em mamíferos fêmeas consistindo de uma combinação de gestageno e estrogênio
MX9603889A (es) Antagonistas de progesterona para la produccion de agente farmaceuticos para el tratamiento de sangrado uterino disfuncional.
ATE344018T1 (de) Kontrazeptives implantat für männer
BR0113376A (pt) Uso de um éster de testosterona, método de tratamento de distúrbios de insuficiência de androgênio, e, sistema de liberação de droga para contracepção masculina
BR0111630A (pt) Espiral para inseto
FI972054A0 (fi) Immunogeenisiä koostumuksia
EP1093816A3 (en) Use of ST1435 in hormonal therapy by transdermal application
AU6788687A (en) A pharmaceutical which can be administered nasally, a process for its preparation, and its use
GB9905663D0 (en) Iodine preparation composition
CO4960657A1 (es) Composicion farmaceutica
ES2062529T3 (es) Uso de alcoholes alifaticos, de c-20 a c-26, para la realizacion de un medicamento destinado al tratamiento de infecciones virales.
DK1237537T3 (da) Præparat i form af en gel til modtagelse af et aktivt stof i oplösning eller suspension, især til anvendelse på en slimhinde, og fremgangsmåde til dets fremstilling
Tong Two Series of Words and Two Series of Terms in the Same Country
鲁传敬 et al. TRANSIENT CAVITY COLLAPSE IN THE VICINITY OF A FLEXIBLE BOUNDARY
ATE161542T1 (de) Oral estrogen wirksame ester des 14 alpha,15 alpha-methylen-estradiols
赵迪 et al. On Stable Minimal Cylinders in 3-manifolds

Legal Events

Date Code Title Description
FC Refusal